ATTD 2026 in Barcelona, Spain

Personalising automated insulin delivery with Personal Glucose Target in myLoop powered by CamAPS FX

Clinical pearls from the symposium

• Use Personal Glucose Target as the main personalisation lever PGT can be adjusted across a wide range (typically 4.4 to 11.0 mmol/L [80–200 mg/dL]), enabling clinicians to balance improvements in Time in Range with protection against hypoglycaemia. 

• Consider tighter targets overnight Nighttime glucose is often more stable and may offer an opportunity to optimise glycaemic control. 

• Consider tighter glucose targets in pregnancy In pregnancy, tighter glycaemic targets are recommended. These targets can be safely achieved, particularly overnight, through the flexibility of PGT settings. 

• Make clinically meaningful adjustments to glucose targets Adjustments should be made in clinically meaningful increments rather than very small changes, to clearly assess their impact. 

• Optimise bolus timing Deliver meal boluses ideally 5–15 minutes before meals. 

• Simplify target settings where possible Using fewer personalised targets may help simplify therapy, particularly in young children. 

Barcelona, ATTD 2026 – During the Advanced Technologies & Treatments for Diabetes (ATTD) 2026 conference, mylife Diabetes Care hosted a scientific symposium exploring how the Personal Glucose Target (PGT) feature enables personalised automated insulin delivery across diverse patient populations. 

The session brought together leading experts to share clinical insights across different patient populations, highlighting the role of glucose targets in balancing Time in Range and hypoglycaemia risk. 

This comes at a time of continued adoption, with more than 100,000 people across multiple countries* now using myLoop. A recent press release introduced CamAPS Liberty, a new fully closed-loop option within the CamAPS FX app. Availability is subject to local regulatory approvals. 

The symposium featured Professor Roman Hovorka (University of Cambridge), Professor Marco Marigliano (University of Verona), and Dr Carmen Quirós (Hospital Universitario La Paz, Madrid), who shared perspectives spanning algorithm development, paediatric care and adult diabetes management.

Personal Glucose Target: the key lever for personalising automated insulin delivery 

Professor Roman Hovorka opened the symposium by outlining the scientific principles behind the CamAPS FX algorithm and the central role of the PGT in tailoring automated insulin delivery. 

Within the CamAPS FX algorithm powering myLoop, the PGT enables the system to adapt to each individual. 

PGT allows clinicians and users to adjust glucose targets according to individual needs and clinical circumstances. Lower targets encourage earlier algorithm responses and are generally associated with lower mean glucose levels and higher Time in Range (TIR), while higher targets may provide additional protection against hypoglycaemia.  

This makes PGT the primary lever for personalising how the algorithm balances glycaemic outcomes and safety across different individuals and clinical situations.

Outcomes vary across populations, with older adults typically achieving higher TIR, while very young children experience greater variability and lower TIR. 

Overnight glucose management was highlighted as a key opportunity for optimisation, as glucose levels tend to be more stable at night, offering an opportunity to optimise glucose targets. 

He also briefly addressed the use of the system in pregnancy, noting that tighter glucose targets can be safely applied in this setting, particularly overnight. 

Personalising AID therapy in very young children 

Building on this scientific foundation, Professor Marco Marigliano shared clinical experience and real-world evidence in very young children, a population characterised by rapidly changing insulin requirements and unpredictable daily routines. 

Young children experience significant variability due to changing insulin needs, irregular eating patterns and spontaneous physical activity. In this context, adjusting the PGT helps clinicians tailor therapy and optimise glycaemic control. 

Real-world evidence presented during the symposium showed that use of myLoop improves glycaemic outcomes in children under six years old. Clinical and real-world data with CamAPS FX, the algorithm powering myLoop, report TIR of approximately 64–67%, while maintaining low Time Below Range (TBR), with improvements of around 11 percentage points sustained over time.1-2 

Data from Professor Marigliano’s centre in Verona also demonstrated significant improvements in a cohort of 40 very young children using myLoop, with mean HbA1c decreasing from around 7.5% to approximately 6.9% over one year, alongside improvements in Time in Range by 15 percentage points. 

He also emphasised the importance of practical management strategies to optimise system performance, including appropriate bolus timing – ideally 5-15 minutes before meals – and careful adjustment of carbohydrate ratios. 

Individualising glucose targets in adult diabetes care 

Closing the symposium, Dr Carmen Quirós discussed how similar principles of personalisation apply in adult diabetes care. 

Adjusting glucose targets allows clinicians to optimise glycaemic outcomes while maintaining safety. However, tighter targets are not always appropriate for everyone. 

Instead, target selection should consider factors such as hypoglycaemia risk, daily routines, lifestyle and personal preferences. Dr Quirós emphasised that clinicians should work closely with individuals using the system to progressively optimise targets and build confidence in automated insulin delivery. 

Towards intelligent and personalised automated diabetes care 

The symposium highlighted a key evolution in diabetes technology: moving beyond automation towards intelligent personalisation. 

Offered by mylife Diabetes Care, myLoop powered by CamAPS FX combines the YpsoPump insulin pump, a compatible continuous glucose monitoring system (Dexcom G6 or Abbott FreeStyle Libre 3) and the CamAPS FX adaptive control algorithm to automatically adjust insulin delivery based on real-time glucose data. With the introduction of CamAPS Liberty, myLoop takes a further step towards fully closed-loop insulin delivery. 

At the centre of the approach is the Personal Glucose Target, which allows clinicians and users to tailor glucose targets according to individual needs and clinical circumstances. 

• 100,000+ people across multiple countries* are now using myLoop  

• 64–67% Time in Range (TIR) achieved in very young children while maintaining low Time Below Range (TBR) in real-world studies1-2 

• ~11% improvement in TIR reported in young children after starting AID2 

• HbA1c reduction from ~7.5% to ~6.9% observed over one year in a cohort of 40 young children using CamAPS FX in Verona 

• 5–15 minutes pre-meal bolus timing identified as an important strategy to optimise outcomes